{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:36:18Z","timestamp":1767983778183,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T00:00:00Z","timestamp":1542844800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s11239-018-1783-2","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T14:57:58Z","timestamp":1542898678000},"page":"409-419","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2019-3893","authenticated-orcid":false,"given":"A.","family":"Franco-Moreno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Cabez\u00f3n-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Palka-Kotlowsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Villamayor-Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Garc\u00eda-Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,22]]},"reference":[{"issue":"3","key":"1783_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/rth2.12102","volume":"2","author":"TF Wang","year":"2018","unstructured":"Wang TF, Li A, Garcia D (2018) Managing thrombosis in cancer patients. Res Pract Thromb Haemost 2(3):429\u2013438","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"1783_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/cancers10080271","volume":"10","author":"H Al-Samkari","year":"2018","unstructured":"Al-Samkari H, Connors JM (2018) The role of direct oral anticoagulants in treatment of cancer-associated thrombosis. Cancers (Basel) 10(8):271","journal-title":"Cancers (Basel)"},{"issue":"11","key":"1783_CR3","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1080\/14656566.2018.1496238","volume":"19","author":"D Imberti","year":"2018","unstructured":"Imberti D, Cimminiello C, Di Nisio M et al (2018) Antithrombotic therapy for venous thromboembolism in patients with cancer: expert guidance. Expert Opin Pharmacother 19(11):1177\u20131185","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"1783_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1024\/0301-1526\/a000684","volume":"47","author":"M Voigtlaender","year":"2018","unstructured":"Voigtlaender M, Langer F (2018) Management of cancer-associated venous thromboembolism\u2014a case-based practical approach. Vasa 47(2):77\u201389","journal-title":"Vasa"},{"issue":"2","key":"1783_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jjcc.2018.02.011","volume":"72","author":"M Mukai","year":"2018","unstructured":"Mukai M, Oka T (2018) Mechanism and management of cancer-associated thrombosis. J Cardiol 72(2):89\u201393","journal-title":"J Cardiol"},{"issue":"6","key":"1783_CR6","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","volume":"33","author":"GH Lyman","year":"2015","unstructured":"Lyman GH, Bohlke K, Khorana AA et al (2015) Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol 33(6):654\u2013656","journal-title":"J Clin Oncol"},{"issue":"12","key":"1783_CR7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s12094-014-1238-y","volume":"16","author":"AJ Mu\u00f1oz Mart\u00edn","year":"2014","unstructured":"Mu\u00f1oz Mart\u00edn AJ, Font Puig C, Navarro Mart\u00edn LM et al (2014) Spanish society for medical oncology. Clinical guide SEOM on venous thromboembolism in cancer patients. Clin Transl Oncol 16(12):1079\u20131090","journal-title":"Clin Transl Oncol"},{"issue":"10","key":"1783_CR8","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1016\/S1470-2045(16)30369-2","volume":"17","author":"D Farge","year":"2016","unstructured":"Farge D, Bounameaux H, Brenner B et al (2016) International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 17(10):e452\u2013e466","journal-title":"Lancet Oncol"},{"key":"1783_CR9","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Venous thromboembolic disease. V2.2018. http:\/\/www.nccn.org . Accessed 24 Oct 2018"},{"issue":"Suppl","key":"1783_CR10","doi-asserted-by":"publisher","first-page":"48S","DOI":"10.1378\/chest.11-2286","volume":"141","author":"GH Guyatt","year":"2012","unstructured":"Guyatt GH, Akl EA, Crowther M et al (2012) American College of Chest Physicians. Introduction to the ninth edition: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(Suppl):48S\u201352S","journal-title":"Chest"},{"issue":"Suppl 6","key":"1783_CR11","doi-asserted-by":"crossref","first-page":"vi85","DOI":"10.1093\/annonc\/mdr392","volume":"22","author":"M Mandala","year":"2011","unstructured":"Mandala M, Falanga A, Roila F. ESMO Guidelines Working Group (2011) Management of venous thromboembolism (VTE) in cancer patients. Ann Oncol 22(Suppl 6):vi85\u2013vi92","journal-title":"Ann Oncol"},{"key":"1783_CR12","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","volume":"162","author":"G Meyer","year":"2002","unstructured":"Meyer G, Marjanovic Z, Valcke J et al (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162:1729\u20131735","journal-title":"Arch Intern Med"},{"key":"1783_CR13","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146\u2013153","journal-title":"N Engl J Med"},{"key":"1783_CR14","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","volume":"119","author":"RD Hull","year":"2006","unstructured":"Hull RD, Pineo GF, Brant RF et al (2006) LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119:1062\u20131072","journal-title":"Am J Med"},{"key":"1783_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/1076029606293692","volume":"12","author":"SR Deitcher","year":"2006","unstructured":"Deitcher SR, Kessler CM, Merli G et al (2006) Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12:389\u2013396","journal-title":"Clin Appl Thromb Hemost"},{"key":"1783_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jama.2015.9243","volume":"314","author":"AYY Lee","year":"2015","unstructured":"Lee AYY, Kamphuisen PW, Meyer G et al (2015) Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 314:677\u2013686","journal-title":"JAMA"},{"key":"1783_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1067\/mva.2001.109336","volume":"33","author":"P L\u00f3pez\u2013Beret","year":"2001","unstructured":"L\u00f3pez\u2013Beret P, Orgaz A, Fontcuberta J et al (2001) Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg 33:77\u201390","journal-title":"J Vasc Surg"},{"key":"1783_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ejvs.2008.11.030","volume":"37","author":"A Romera","year":"2009","unstructured":"Romera A, Cairols MA, Vila-Coll R et al (2009) A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 37:349\u2013356","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"1","key":"1783_CR19","first-page":"150","volume":"114","author":"S Schulman","year":"2015","unstructured":"Schulman S, Goldhaber SZ, Kearon C et al (2015) Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 114(1):150\u2013157","journal-title":"Thromb Haemost"},{"issue":"1","key":"1783_CR20","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","volume":"1","author":"MH Prins","year":"2014","unstructured":"Prins MH, Lensing AW, Brighton TA et al (2014) Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of treatment of symptomaticvenous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 1(1):e37\u2013e46","journal-title":"Lancet Haematol"},{"issue":"12","key":"1783_CR21","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1111\/jth.13153","volume":"13","author":"G Agnelli","year":"2015","unstructured":"Agnelli G, Buller HR, Cohen A et al (2015) Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 13(12):2187\u20132191","journal-title":"J Thromb Haemost"},{"issue":"3","key":"1783_CR22","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.thromres.2015.07.011","volume":"136","author":"F Posch","year":"2015","unstructured":"Posch F, K\u00f6nigsbr\u00fcgge O, Zielinski C et al (2015) Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 136(3):582\u2013589","journal-title":"Thromb Res"},{"issue":"7","key":"1783_CR23","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/jth.12230","volume":"11","author":"G Raskob","year":"2013","unstructured":"Raskob G, B\u00fcller H, Prins M et al (2013) Hokusai-VTE Investigators. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study-methodological implications for clinical trials. J Thromb Haemost 11(7):1287\u20131294","journal-title":"J Thromb Haemost"},{"issue":"7","key":"1783_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P et al (2018) Hokusai VTE cancer investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615\u2013624","journal-title":"N Engl J Med"},{"issue":"20","key":"1783_CR25","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (select-d). J Clin Oncol 36(20):2017\u20132023","journal-title":"J Clin Oncol"},{"key":"1783_CR26","unstructured":"https:\/\/clinicaltrials.gov\/ . Accessed 21 Sept 2018"},{"issue":"2","key":"1783_CR27","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s11239-016-1429-1","volume":"43","author":"S Mantha","year":"2017","unstructured":"Mantha S, Laube E, Miao Y, Sarasohn DM et al (2017) Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. J Thromb Thrombolysis 43(2):166\u2013171","journal-title":"J Thromb Thrombolysis"},{"key":"1783_CR28","doi-asserted-by":"crossref","unstructured":"Cohen AT, Maraveyas A, Beyer-Westendorf J et al. COSIMO Investigators. COSIMO\u2014patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study. Thromb J 16:21","DOI":"10.1186\/s12959-018-0176-2"},{"issue":"9","key":"1783_CR29","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1055\/s-0038-1668523","volume":"118","author":"G Agnelli","year":"2018","unstructured":"Agnelli G, Becattini C, Bauersachs R et al (2018) Caravaggio study investigators. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thromb Haemost 118(9):1668\u20131678","journal-title":"Thromb Haemost"},{"key":"1783_CR30","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ajh.25059","volume":"93","author":"MB Streiff","year":"2018","unstructured":"Streiff MB, Milentijevic D, McCrae K et al (2018) Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. Am J Hematol 93:664\u2013671","journal-title":"Am J Hematol"},{"key":"1783_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.thromres.2017.02.003","volume":"152","author":"I Theberge","year":"2017","unstructured":"Theberge I, Bowdridge J, Forgie MA et al (2017) Rivaroxaban shows promise as effective therapy for cancer patients with venous thromboembolic disease. Thromb Res 152:4\u20136","journal-title":"Thromb Res"},{"key":"1783_CR32","doi-asserted-by":"publisher","first-page":"695P","DOI":"10.1093\/annonc\/mdw371.87","volume":"27","author":"SR Seo","year":"2016","unstructured":"Seo SR, Ryu M-H K, Y-K K, K-P et al (2016) Oral rivaroxaban versus subcutaneous low molecular weight heparin treatment for venous thromboembolism in patients with upper gastrointestinal, hepatobiliary and pancreatic cancer. Ann Oncol 27:695P","journal-title":"Ann Oncol"},{"key":"1783_CR33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.thromres.2016.12.016","volume":"150","author":"JA Ross","year":"2017","unstructured":"Ross JA, Miller MM, Rojas Hernandez CM (2017) Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: a retrospective analysis. Thromb Res 150:86\u201389","journal-title":"Thromb Res"},{"key":"1783_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.thromres.2017.04.001","volume":"155","author":"AGG Turpie","year":"2017","unstructured":"Turpie AGG, Mantovani LG, Haas S et al (2017) Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study. Thromb Res 155:23\u201327","journal-title":"Thromb Res"},{"key":"1783_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2018.02.144","author":"A Li","year":"2018","unstructured":"Li A, Garcia DA, Lyman GH et al (2018) Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res. https:\/\/doi.org\/10.1016\/j.thromres.2018.02.144","journal-title":"Thromb Res"},{"key":"1783_CR36","doi-asserted-by":"publisher","first-page":"107602961880079","DOI":"10.1177\/1076029618800792","volume":"24","author":"DM Sobieraj","year":"2018","unstructured":"Sobieraj DM, Baker WL, Smith E et al (2018) Anticoagulation for the treatment of cancer-associated thrombosis: a systematic review and network meta-analysis of randomized trials. Clin Appl Thromb Hemost 24:1076029618800792","journal-title":"Clin Appl Thromb Hemost"},{"issue":"9","key":"1783_CR37","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1111\/jth.14219","volume":"16","author":"AA Khorana","year":"2018","unstructured":"Khorana AA, Noble S, Lee AYY et al (2018) Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 16(9):1891\u20131894","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-018-1783-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-018-1783-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-018-1783-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T19:58:41Z","timestamp":1605470321000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-018-1783-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,22]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1783"],"URL":"https:\/\/doi.org\/10.1007\/s11239-018-1783-2","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,22]]},"assertion":[{"value":"22 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}